reports
Regeneron Announces Investor Conference Presentation
Regeneron Announces Investor Conference Presentation TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026. The session may be accessed from the "Investors & Media" page of Regeneron's website at . A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commer...
Range Resources Corp : 2 directors
Two Directors at Range Resources Corp sold after exercising options/gave away/sold 54,376 shares at between 0.000USD and 41.995USD. The significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...
ANI Pharmaceuticals Inc: 1 director
A director at ANI Pharmaceuticals Inc sold 6,000 shares at 74.230USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Boyd Gaming Corp: 2 directors
Two Directors at Boyd Gaming Corp sold after exercising options/sold 43,454 shares at between 83.590USD and 85.860USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...
Range Increases Quarterly Dividend By 11%
Range Increases Quarterly Dividend By 11% FORT WORTH, Texas, Feb. 27, 2026 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced that its Board of Directors declared a quarterly cash dividend on its common stock for the first quarter. A dividend of $0.10 per common share is payable on March 27, 2026 to stockholders of record at the close of business on March 13, 2026. This represents an 11% increase to Range’s quarterly cash dividend and provides an annualized dividend of $0.40 per share. RANGE RESOURCES CORPORATION (NYSE: RRC) is a leading U.S. independent natural ...
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spo...
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and...
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 F...
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenue...
Oceaneering International Inc: 9 directors
Nine Directors at Oceaneering International Inc sold/gave away 132,612 shares at between 0.000USD and 38.960USD. The significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the comp...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Range Resources Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 25 February 2026 in which we reassessed the appropriateness of the ratings in t...
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Th...
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States’ oldest and most prestigious science and mathematics competition for high school seniorsSince the start of Regeneron’s sponsorship in 2017 through this year’s STS, Regeneron and the Society have engaged an...
Range Announces Fourth Quarter 2025 Results and 2026 Guidance
Range Announces Fourth Quarter 2025 Results and 2026 Guidance FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced its fourth quarter 2025 financial results and plans for 2026. Full-Year 2025 Highlights – Cash flow from operating activities of $1.2 billionCash flow from operations, before working capital changes, of $1.3 billionSigned 10-year supply agreement for 75 Mmcf per day for a Midwest power plantProduction averaged 2.24 Bcfe per day, comprised of approximately 69% natural gasAll-in capital spending of $674 million, or $0.8...
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medic...
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven ...
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
ANI Pharmaceuticals to Present at Upcoming Investor Conferences PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will present at the following investor conferences: Raymond James & Associates’ 47th Annual Institutional Investors Conference on Tuesday, March 3, 2026, at 7:30am ETLeerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 3:00pm ETBarclays 28th Annual Globa...
Moody's Ratings says Gilead's acquisition of Arcellx improves diversit...
Moody's Ratings (Moody's) said that Gilead Sciences, Inc.'s ("Gilead"; A3 positive) acquisition of Arcellx will improve Gilead's product and therapeutic diversity through full ownership of its key cell therapy pipeline product anito-cel for multiple myeloma. Gilead announced on 23 February that it e...
Garetosmab Biologics License Application Accepted for FDA Priority Rev...
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) toda...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Finan...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to ...
CTS Corporation Declares a Dividend
CTS Corporation Declares a Dividend LISLE, Ill., Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE: CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on April 24, 2026, to shareholders of record at the close of business on March 27, 2025. About CTS CTS Corporation (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products t...
Regeneron Pharmaceuticals Inc: 2 directors
Two Directors at Regeneron Pharmaceuticals Inc sold/sold after exercising options 2,136 shares at between 778.516USD and 778.526USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...
Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Regen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.